DA
LBPH

Denali Advisors’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Denali Advisors’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,300
Closed -$201K – 478
2024
Q1 		$201K Buy
+9,300
New +$203K 0.06% 225

Other funds holding LBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Denali Advisors's LBPH Position: Q2 2024 in Review

Denali Advisors sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q2 2024, closing a stake of 9,300 shares — an estimated $201K sold.

Denali Advisors first reported a position in LBPH in Q1 2024 and held it in 1 quarter. The position peaked at $201K in Q1 2024. 100 funds tracked by Wall St. Rank hold LBPH as of Q2 2024.

  • Denali Advisors reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 9,300 Longboard Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $201K.
  • Denali Advisors first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Denali Advisors's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $201K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.